Menu Contact
Warner Law Offices PLLC
LOCAL: 304-345-6789
TOLL FREE: 866-344-4460

New Study Shows Invokana Increases the Risk of Amputations

Warner Law Offices has recently become aware that the Type 2 diabetes drug, Invokana, puts users at an increased risk for leg, foot and toe amputations. The FDA issued the first safety warning regarding Invokana and amputation based on interim analysis of two clinical trials. Both studies have now been concluded and final results confirm that Invokana may double the amputation risk. Based on these final results, the FDA has issued a more severe, "black box warning" for Invokana.


Johnson & Johnson, the manufacturer of Invokana, has suffered one issue after another over the past few years, including those associated with transvaginal mesh, metal hip implants, talcum powder ovarian cancer claims, and now more issues with Invokana. Warner Law Offices is taking on all of these cases in an effort hold this corporation accountable for its failure to provide safe medical products.

Our attorneys know that only by banding together and sharing information can we effectively fight the propensity of big manufacturing companies to rush untested and dangerous products to the marketplace.

If you or a loved one have had a leg, foot or toe amputation while taking Invokana, please call me today. It is important that all those who have been injured join the fight against defective products while also getting the compensation they deserve.

No Comments

Leave a comment
Comment Information
10 Best 2014 - 2016 | 3 Years Client Satisfaction | American Institute of Personal Injury Attorneys Avvo Rating 10.0 Superb | Top Attorney Personal Injury Lead Counsel Rated Rue Ratings | Best Attorneys of America | Lifetime Charter Member 2016 Sponsor Insight | Newsweek | Premier Law Firms 2016 Nations Premier | NAOPIA | Top Ten Attorney Personal Injury The National Trial Lawyers | Top 100 Trial Lawyers Young Guns | Class of 2014 America's Top 100 Attorneys Mass Tort Trial Lawyers | Top 25

Privacy Policy | Business Development Solutions by FindLaw, part of Thomson Reuters.